Back

Which therapy performs best across clinical domains in transthyretin amyloid cardiomyopathy? a frequentist network meta-analysis

30 August 2026 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: New insights into cardiac amyloidosis Infiltrative Myocardial Disease ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Adolfo Calderon Fernandez

Tijuana (Mexico)

7 More presentations in this session

Presentation thumbnail
Decoding peripartum cardiomyopathy through multi-omics: circulating and cellular signatures from the Italian multicenter registry
Doctor M. Carotenuto (Naples, IT)
Abstract
Presentation thumbnail
Premature hypertensive heart disease in working-age adults: global burden, inequalities and missed prevention opportunities (GBD 2021)
Doctor X. Dong (Beijing, CN)
Abstract
Presentation thumbnail
Vascular dysfunction is associated with symptom severity and quality of life in wild-type transthyretin amyloid cardiomyopathy
Mr N. Ogasawara (Akita, JP)
Abstract
Presentation thumbnail
Diagnostic utility of three clinical scoring systems for transthyretin amyloid cardiomyopathy in elderly Asian patients with heart failure with preserved ejection fraction
Doctor M. Chen (Taipei, TW)
Abstract
Presentation thumbnail
Improvement of health status with acoramidis in patients with wild-type and variant transthyretin amyloid cardiomyopathy: KCCQ domains analysis from the ATTRibute-CM study
Doctor N. Sarswat (Chicago, US)
Abstract

Access the full session

Session thumbnail
New insights into cardiac amyloidosis

The Event

Event poster

ESC Congress 2026

30 August 2026 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy
29 June 2021
thumbnail
Congress Presentation
Effectiveness of empiric cardioprotective therapy in patients receiving cardiotoxic chemotherapies: systematic review & bayesian network meta-analysis
9 April 2022
thumbnail
Congress Presentation
Optimizing treatment strategies for transthyretin amyloid cardiomyopathy: a comprehensive Bayesian network meta-analysis of disease-specific therapies
1 September 2025
thumbnail
Congress Presentation
Comparison of performance of heart failure and disease-specific staging systems for prognostic stratification in transthyretin amyloid cardiomyopathy
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources